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ARTICLE
Real-Time and Wireless Assessment of Adherence to 
Antiretroviral Therapy With Co-Encapsulated Ingestion 
Sensor in HIV-Infected Patients: A Pilot Study
Eric S. Daar1,*, Marc I. Rosen2, Yan Wang3, Lisa Siqueiros1, Jie Shen4, Mario Guerrero1, Di Xiong3, John Dao5, Todd Young5, 
Katya Corado1, Courtney V. Fletcher6 and Honghu Liu4
Adherence with antiretroviral therapy is important for preventing disease progression and HIV transmission. The co-en-
capsulated pill sensor system sends a signal through a cutaneous patch and allows real-time monitoring of pill ingestion. 
A 16-week pilot study used a sensor system in 15 HIV-infected individuals with real-time monitoring of pill-taking with a 
personalized short message system text. System acceptability was assessed by survey at weeks 4, 8, 12, and 16. Follow-up 
occurred in 80% of subjects through 8 weeks. The system effectively collected measures of pill ingestion, which triggered 
text message reminders. Only 2 of 14 participants stated that co-encapsulated pills were “unable to take” or “poorly toler-
ated.” At least 75% of respondents stated at each visit that the patch was very or somewhat comfortable. With regard to text 
message reminders, only 10–15% of the participants at any visit did not find the messages to be helpful. Larger studies will 
define the utility of this system to assess antiretroviral adherence relative to standard measures.
The availability of potent antiretroviral (ARV) therapy has 
transitioned HIV infection into a chronic disease. Maximizing 
the benefits of ARV therapy requires optimal adherence with 
pill-taking and clinic visits to reach viral suppression, which 
reduces likelihood of disease progression, emergence of 
drug-resistant virus, and HIV transmission.1–4 Adherence 
can be challenging to quantify and has traditionally been 
done with self-report questionnaires and in clinical trials, 
often incorporating pill counts and pharmacy refill records.5 
Additional methods have been developed using electronic 
monitoring, such as Medication Event Monitoring Systems 
that records when pill bottles are opened.6 Although this 
and related technologies advance the ability to measure 
adherence, they are limited to inferred estimates of adher-
ence because they depend upon the pill-taking individuals’ 
cooperation, do not directly record medication taking, and 
may not report adherence in real-time. Innovative monitor-
ing systems have been created that are able to detect re-
al-time opening through Bluetooth and Wi-Fi technologies 
vs. historical pill bottle opening, as with Medication Event 
Monitoring Systems.7 However, many of these only detect 
when the pill bottle is opened but not when the pill is actually 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔  There is growing body of data using novel co-en-
capsulation of ingestion sensor to track adherence. This 
technology has not yet been applied to those chronically 
infected with HIV on antiretroviral (ARV) therapy.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  The implementation, participant acceptability, and sat-
isfaction of the co-encapsulation of ingestion sensor and 
ARVs with real-time monitoring and short message sys-
tem reminders in HIV-infected individuals.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔  The study demonstrates that the ingestible sensor 
system using real-time monitoring with personalized short 
message system can be implemented with commonly 
used ARV agents. The study further provides an assess-
ment of the acceptability of taking co-encapsulated ARV/
sensor, using a dermal patch with a paired mobile device 
and an overview as to how study subjects felt about using 
the overall system.
HOW MIGHT THIS CHANGE CLINICAL PHARMA- 
COLOGY OR TRANSLATIONAL SCIENCE?
✔  This pilot study sets the stage for implementing novel 
monitoring technology for HIV-infected patients, particu-
larly those who are poorly adherent to ARVs, to further 
define utility as well as ability to assess adherence in com-
parison to standard measures.
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ingested. It also does not allow use of other simple technol-
ogy to assist with adherence, such as pill boxes.
A novel technology called the Proteus Digital Health 
Feedback (PDHF) system (Proteus Digital Health, Redwood, 
CA) was approved by the US Food and Drug Administration 
in 2012 and given clearance in 2015 for real-time monitoring 
of medication ingestion, with additional provision for auto-
mated short message system (text) reminders.8 The PDHF 
system involves use of an ingestible sensor made of an inert 
edible material that can be co-encapsulated (Capsugel, 
Greenwood, SC) with prescribed medications. The ingestible 
sensor is activated when stomach liquid dissolves the encap-
sulating material, and the sensor is then detected by a mon-
itor-patch worn over patient’s upper abdomen. The patch 
contains a microchip and a tiny battery. The microchip sends 
a Bluetooth signal to the individual’s mobile device (e.g., tab-
let or cell phone), which, in turn, sends an encrypted mes-
sage to a central server, thus allowing for a real-time signal 
that is day and time stamped for when a dose has been taken 
(Figure 1). A short message system can be programmed in 
response to the receipt (or not) of the ingestion signal, for 
example, a reinforcing message if a dose is taken and a re-
minder after a scheduled dose is missed. This technology has 
been used in those treated for a variety of disease states, in-
cluding hypertension, mental health conditions, tuberculosis, 
and organ transplantation.9–13 Studies have reported at least 
95% detection sensitivity and 99.7% specificity.8,12 However, 
this device has not yet been tested for ARV therapy use in 
HIV-infected individuals. We now report the results of a pilot 
study to introduce this system, along with personalized text 
reminders to HIV-infected individuals to assess functionality 
and participant acceptability and satisfaction with the system.
MATERIALS AND METHODS
The current study was designed to pilot the PDHF system in 
HIV-infected individuals on ARV therapy and to determine 
approaches to maximize utilization and assess acceptabil-
ity in 15 HIV-infected individuals with evidence of poor ad-
herence. This was designed to address issues related to 
real-time data handling, co-encapsulation, patch use, and 
medication delivery along with personalized text messaging 
feedback. Co-encapsulation was performed by investiga-
tional drug pharmacists per manufacturer guidelines and as 
summarized by Browne et al.,14 using the same size gelatin 
cap for all medications, regardless of their size. Bioavailability 
of utilized co-encapsulated ARVs was previously presented.15 
The personalized text message was developed with input 
from each study participant. For the pilot study, the system 
was programed to send a message if a dose was not de-
tected to be taken within 1 hour of when it was scheduled. If 
a dose was missed, the system also sent a customized pre-
dose reminder for future doses with each participant being 
able to request that reminders be stopped at any time.
We recruited HIV-infected individuals in HIV care who were 
receiving stable ARV therapy with evidence of suboptimal 
adherence as defined by < 90% adherence over the last 28 
days by self-report, or over the last 6 months as perceived 
by the treating clinician based on missed appointments, re-
ported missed doses, or viral load elevations. In order to be 
enrolled, participants needed to indicate that they tolerated 
a single co-encapsulated medication at the time of screen-
ing and be able to provide informed consent. Subjects were 
excluded if they were unable to follow study procedures, had 
evidence of cognitive deficits or substance use that were 
thought by the investigator to render them unable to follow 
study procedures, or were pregnant. The study was reviewed 
and approved by the Institutional Review Board at the Los 
Angeles Biomedical Research Institute at Harbor-University of 
California, Los Angeles Medical Center and the David Geffen 
School of Medicine at University of California, Los Angeles.
Enrolled individuals had one of the ARV pills they were 
routinely taking co-encapsulated during the 16  weeks of 
study, a process that we performed per manufacturer guide-
lines by an investigational drug pharmacist.14 Participants 
were provided instructions on how to use the PDHF sys-
tem, including patch use and synchronization with the patch 
and mobile devices. Participants were contacted over the 
phone on days 3 and 14 to assess early problems and then 
scheduled for in-person study visits at weeks 4, 8, 12, and 
16 at which they completed surveys related to satisfaction 
with different aspects of the system and perceived benefits. 
Figure 1 Monitoring system (courtesy of Proteus Digital Health, Redwood, CA).
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Results were tabulated and presented in a descriptive fash-
ion for the purposes of this pilot study.
RESULTS
All 15 participants screened met inclusion criteria and were 
enrolled. The baseline characteristics of the enrolled indi-
viduals are summarized in Table  1. Nine of the subjects 
were on single-tablet ARV regimens that included elvite-
gravir/cobicistat/emtricitabine/tenofovir alafenamide (n = 1), 
tenofovir alafenamide/emtricitabine/rilpivirine (n  =  3), and 
abacavir/lamivudine/dolutegravir (n = 5), with the remaining 
being on the fixed-dose combination of tenofovir alafenam-
ide/emtricitabine given daily as the co-encapsulated drug 
along with an unencapsulated pharmacologically boosted 
protease inhibitor. Although all met criteria for concerns for 
poor adherence, 10 had plasma HIV-1 RNA levels < 20 cop-
ies/mL at the time of their most recent testing. Key aspects 
of the approved system functioned throughout study, in-
cluding ability for ingestion information to be received by 
patch and relayed to the server, as well as automatic per-
sonalized text messages sent after 1 hour of a missed dose, 
and again as predose reminders for those who previously 
missed a dose.
Of the 15 participants, 1 stopped wearing the patch be-
fore week 4 due to persistent skin reaction, but remained 
in the study follow-up. Two withdrew consent, 1 after week 
4 and the other after week 8 visits. The former stated he 
stopped due to personal medical issues unrelated to the 
study and the latter stating the PDHF system was too com-
plicated. One participant was lost to follow-up after week 8. 
Therefore, 12 subjects remained on the study throughout, 
although there were several that intermittently missed select 
study visits. The acceptability and satisfaction of different 
aspects of the system were collected in those that presented 
for each of the follow-up visits. Key survey responses were 
assessed regarding taking co-encapsulated pills, using the 
cutaneous patch, receiving text messages, and overall utili-
zation of the system.
As shown in Tables  2−4, attrition and missed visits re-
sulted in 8−10 of the 15 original participants having data 
available at the final week 16 assessments. Participants were 
queried regarding tolerability of co-encapsulated medica-
tions. More than 70% stated during the 4-week and 8-week 
visits, when there was the highest rate of follow-up, that it 
was well-tolerated (Table 2). Additional responses related to 
tolerability of co-encapsulated pills were consistent with this 
(Table S1). Participants were also asked about the use of the 
patch. Although one participant had significant skin reaction 
resulting in it being stopped early, overall responses were 
good, including during week 4 and 8 visits when there was 
the highest rate of responses. For example, when asked how 
comfortable they were with the patch, >  70% responded 
that it was either very comfortable or somewhat comfort-
able. Approximately 15–25% at each visit stated the patch 
was somewhat uncomfortable with zero to one participant 
at each visit stating it was very uncomfortable. Additional 
responses related to patch use are summarized in Table S2.
Text messaging was only utilized for those who missed a 
dose, after which it was sent prior to subsequent scheduled 
doses unless the participant requested it to be stopped. All 
participants missed at least one dose and received a text 
message during the course of the study. It is noteworthy that 
only 2 of the 15 requested that the predose text reminder 
be stopped. Based upon those who responded, well over 
70% stated that they were very comfortable receiving text 
messages through the system (Table  3). In response to 
whether participants thought the text messages were help-
ful, the results were more variable, but most either strongly 
or somewhat agreed that it was helpful (Table 3). Additional 
responses to the text messaging aspect of the system are 
summarized in Table S3.
Questions also probed the level of satisfaction and per-
ceived usefulness of the overall system. In response to the 
question, “The sensor system is helpful,” a majority, includ-
ing 85% and 75% of those responding at weeks 4 and 8, 
respectively, noted that they somewhat or strongly agreed. 
In response to the question “Overall I am satisfied with the 
sensor system,” ~ 55% of respondents at week 4 and 83% 
at week 8 stated that they somewhat or strongly agreed 
(Table  4). Additional responses to the acceptability of the 
overall system are included in Table S4.
DISCUSSION
This pilot study assessed the functionality, partici-
pant  satisfaction with and potential utility of the novel 
PDHF system that incorporates the use of co-encapsu-
lated medication with ingestible sensor, application of a 
Table 1 Baseline characteristics
Characteristics (n = 15) Mean (SD) or n (%)
Age, years 48 (6.9)
Sex
Male 13 (86.7)
Race and ethnicity
Black 7 (46.7)
Hispanic white 6 (40.0)
Non-Hispanic white 2 (13.3)
Self-identified major risk factor for HIV infection
MSM 9 (60.0)
Homosexual 5 (33.3)
i.v. drug use 1 (6.7)
Co-encapsulated ARV
TAF/FTC 6 (40.0)
EVG/COBI/FTC/TAF 1 (6.7)
TAF/FTC/RPV 3 (20.0)
ABC/3TC/DTG 5 (33.3)
Most recent CD4 count, cells/uL [min, 
max]
774.2 [275, 1375]
Most recent plasma HIV RNA
< 20 copies/mL 10 (66.7)
≥ 20 copies/mL 4 (26.7)
Unknown 1 (6.7)
ABC/3TC/DTG, abacavir/lamivudine/dolutegravir; ARV, antiretroviral; EVG/
COBI/FTC/TAF, elvitegravir/cobicistat/tenofovir alafenamide/emtricitabine; 
MSM, Men who have sex with men; TAF/FTC, tenofovir alafenamide/emtricit-
abine; TAF/FTC/RPV, tenofovir alafenamide/emtricitabine/rilpivirine.
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patch, real-time monitoring of adherence through a mo-
bile device, and personalized text message reminders. 
There was reasonable follow-up during the first 8 weeks, 
which fell off after that due to two withdrawals of con-
sents, one of which was due to complexity of the system. 
There was an additional person lost to follow-up with oth-
ers intermittently missing scheduled visits. The text mes-
sage system worked as programed through the course of 
follow-up. For those with follow-up, all but one subject per 
visit stated they were able to tolerate taking the co-en-
capsulated pill. One participant stopped the patch early 
due to a skin reaction, with one to three participants per 
visit stating that it was somewhat or very uncomfortable. 
Only one to two per visit did not find the text messaging 
to be helpful, with similar numbers not finding the overall 
system to be helpful.
The PDHF system has been used in a variety of patient 
populations in whom treatment adherence is important, 
such as those with hypertension, mental health conditions, 
tuberculosis, and transplantation.9–12 The PDHF system 
has proven to be highly accurate for detecting inges-
tions and without serious adverse events.8 The satisfac-
tion responses in our pilot were similar to those previously 
reported in patients with diseases other than HIV. For ex-
ample, Belknap et  al.12 studied 30 individuals treated for 
tuberculosis with 20 of them completing a post-treatment 
survey. Of those surveyed, 83% said they were comfort-
able using the system with only three  device-related ad-
verse events, all of which were skin irritation. Satisfaction 
was similar in other studies, such as one that included 
37 individuals monitored for 16 weeks of their hyperten-
sion treatment. In this case, 40% complained of mild and 
Table 2 Participant satisfaction with co-encapsulated pill/sensor and patch
 
Week 4 Week 8 Week 12 Week 16
N = 14, n (%) N = 13, n (%) N = 9, n (%) N = 10, n (%)
How well do you tolerate the co-encapsulated antiretroviral medications?a 
Well tolerated 10 (71.4) 10 (76.9) 9 (100) 8 (80.0)
Satisfactory 1 (7.1) 1 (7.7) 0 (0) 2 (20.0)
Can be tolerated 2 (14.3) 1 (7.7) 0 (0) 0 (0)
Poorly tolerated 0 (0) 1 (7.7) 0 (0) 0 (0)
Unable to take 1 (7.1) 0 (0) 0 (0) 0 (0)
 
Week 4 Week 8 Week 12 Week 16
N = 14, n (%) N = 13, n (%) N = 8, n (%) N = 8, n (%)
How comfortable are you with the patch?
Very comfortable 3 (21.4) 6 (46.2) 2 (25.0) 4 (50.0)
Somewhat comfortable 8 (57.1) 4 (30.8) 4 (50.0) 3 (37.5)
Somewhat uncomfortable 2 (14.3) 2 (15.4) 2 (25.0) 1 (12.5)
Very uncomfortable 1 (7.1) 1 (7.7) 0 (0) 0 (0)
aAll medications, regardless of size, were co-encapsulated with the same size gelatin capsule.
Table 3 Participant satisfaction and perceived utility of short text messaging system
 
Week 4 Week 8 Week 12 Week 16
N = 14, n (%) N = 13, n (%) N = 8, n (%) N = 8, n (%)
How comfortable are you with receiving text messages through the system?
Very comfortable 7 (50.0) 7 (53.9) 5 (62.5) 5 (62.5)
Somewhat comfortable 5 (35.7) 5 (38.5) 1 (12.5) 2 (25.0)
Somewhat uncomfortable 2 (14.3) 0 (0) 1 (12.5) 1 (12.5)
Not applicablea 0 (0) 1 (7.7) 1 (12.5) 0 (0)
 
Week 4 Week 8 Week 12 Week 16
N = 14, n (%) N = 12, n (%) N = 9, n (%) N = 9, n (%)
The text messages are helpful
Strongly agree 5 (35.7) 3 (25.0) 5 (55.6) 3 (33.3)
Somewhat agree 5 (35.7) 3 (25.0) 0 (0) 0 (0)
Neutral 1 (7.1) 3 (25.0) 2 (22.2) 3 (33.3)
Somewhat disagree 0 (0) 0 (0) 0 (0) 1 (11.1)
Strongly disagree 2 (14.3) 0 (0) 1 (11.1) 0 (0)
Not applicablea 1 (7.1) 3 (25.0) 1 (11.1) 2 (22.2)
aText messages were only sent if a dose was missed, so they were not received by everyone.
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transient skin patch-associated irritation with 90% re-
sponding that they were satisfied with the co-encapsulated 
pill, and 75% stating that the overall experience was pos-
itive.11 Eisenberger et al.9 reported a study of 20 patients 
who underwent kidney transplantation using the PDHF 
system with seven experiencing a rash or erythema from 
the patch, all occurring in the first 4 weeks of follow-up 
with two stopping because of this adverse event.
Our study explored the acceptability and satisfaction of 
the PDHF system using co-encapsulated ARVs. Although 
there were concerns about the size of the co-encapsulated 
pills, all screened patients were able to take them and most 
found them to be acceptable for use. This issue should be-
come even less of a concern as HIV treatments continue to 
evolve toward smaller pills with many commonly used regi-
mens. Future studies will assess acceptability of the system 
in select groups, including those with the greatest adher-
ence problems. Larger studies will also need to consider 
the benefits relative to the costs of this novel intervention to 
improve treatment adherence.
In summary, this pilot study demonstrated that the PDHF 
system was able to collect real-time ingestion data and au-
tomatically transmit reminder text messages to HIV-infected 
individuals taking ARV therapy. In addition, data were col-
lected on the overall acceptability of different aspects of the 
system in this patient population. The information and ex-
perience gained from this pilot study set the stage for future 
studies to assess whether this novel system is capable of 
monitoring real-time ingestion of ARVs, which would allow 
for immediate interventions in response to pill-taking lapses. 
The goal of real-time monitoring is to identify early problems 
with adherence and intervene to enhance viral suppression 
for the good of the HIV-infected individuals and to minimize 
their risk of transmitting HIV to others.
Supporting Information. Supplementary information accompa-
nies this paper on the Clinical and Translational Science website (www.
cts-journal.com).
Tables S1–S4.
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